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Abstract
Leprosy is a chronic infectious disease caused by Mycobacterium leprae that has a predi-
lection for peripheral nerves, especially Schwann cells (SCs). Leprosy medications may 
only eradicate the bacteria without preventing or recovering peripheral nerve damage. 
Early nerve damage detection is necessary. The expression of Krox-20 in Schwann cells 
will be examined immunohistochemically, and the level of neuron growth factor (NGF), 
neuregulin 1 (NRG1), protein 0 (P0), and peripheral myelin protein 22 (PMP22) will 
be examined in the blood plasmas. A significant decrease was noticed in Krox-20 and 
NGF, NRG1, P0, and PMP22 level (p < 0.05) in disability degree 1 compared to degree 0. 
Studies proved that markers have shown promising results; Krox-20, NGF, NRG1, P0, 
and PMP22 could be useful diagnostic tools for early peripheral nerve damage detection 
in leprosy.
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1. Introduction
1.1. Background
Leprosy is a chronic infectious disease caused by Mycobacterium leprae and has predilection for 
the skin and peripheral nerves, especially in Schwann cells (SCs) [1–4]. During infection, M. 
leprae causes peripheral nerve damage and even causes disability and deformity in patients. 
Although the anti-leprosy drug treatment can already eradicate the bacteria, disability and 
deformity that occur cannot be restored and neither can the function of the nerve that has been 
lost. By understanding the mechanism of nerve damage caused by M. leprae, it is expected that 
nerve damage can be prevented [5].
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Until now leprosy treatment is only for eradication of bacteria, but it cannot prevent or cure 
peripheral nerve damage and its components, so early detection to determine the presence 
of bacteria in Schwann cells is important [6, 7]. Several studies in early detection of nerve 
damage by invasion of M. leprae have been conducted, namely, using ultrasound to detect 
peripheral nerve damage [8], vasomotor reflex and sympathetic skin responses [9], electro-
physiology of the peripheral nerves involved [10], and examining axonal markers on skin 
lesions [11]. There is Ridley-Jopling classification of leprosy based on clinical, bacteriological, 
histological, and immunological symptoms. Based on bacteriological examination, there are 
two types of leprosy: paucibacillary (PB) and multibacillary (MB). PB types include tubercu-
loid type (TT) and borderline tuberculoid (BT) in the Ridley-Jopling classification, whereas 
MB types include borderline-borderline (BB), borderline-lepromatous (BL) leprosy, and lep-
romatous leprosy (LL) types [12].
According to the WHO, the levels of disability in leprosy patients are divided into three 
degrees, ranging from the absence of symptoms to apparent damage or disability [13]. In 
general, according to Seddon, peripheral nerve damage is divided into three, namely, neuro-
praxia, axonotmesis, and neurotmesis, whereas in leprosy nerve damage occurs as a result of 
demyelination of peripheral nerves [14].
In the central nervous system (CNS), myelin is formed by oligodendrocyte. Myelin in the CNS 
has a spiral structure such as peripheral nerve myelin which has an inner mesaxon and an 
outer mesaxon that ends in a loop or cytoplasmic junction. The cytoplasm of glia in the CNS 
is confined to only a portion of the myelin sheath. The glia junction continues with the oligo-
dendrocyte plasma membrane through a layered process. One oligodendrocyte can eliminate 
about 40 or more axons, whereas in the peripheral nervous system (PNS), the myelin deposi-
tion of an axon can reach up to 100 layers of myelin [15].
Schwann cell differentiation is governed by the expression of certain transcription factors. 
After receiving signals from axons, immature Schwann cells including NRG1 will increase 
the expression of some transcription factors such as NFκB, Oct-6, and Brn2. These factors 
will stimulate initiation of the promyelination stage whereby the Schwann cell will interact 
with the axon and begin to express the initial myelination marker. An increase in the Krox-
20 gene requires Schwann cells to initiate the myelination process and express the specific 
protein of myelin. In mature nerves, Schwann cells that do not express Krox-20 will remain 
nonmyelinated cells. In the injury condition, c-Jun and Sox-2 will increase rapidly. This will 
lead to a decrease in Krox-20 and Schwann cell differentiation. Cross-resistance Krox-20 and 
c-Jun will stimulate the switch of complex transcription. Promyelination signals from axons 
such as neuregulin will result in Krox-20 expression via the phosphatidylinositol-3 kinase 
(PI3K) pathway. The activation of the Janus kinase (JNK) pathway during the injury period 
will stimulate c-Jun expression. However, the signals that activate these pathways in Schwann 
cells are still not known [15].
The study evaluated the Krox-20 expression on Schwann cells in the skin biopsy of leprosy 
patients, and it was observed that there was a significant difference of Krox-20 expression 
among patients with degree of disability 0 and 1. (T-tailed test shows F = 8.881 with p = 0.000 
(p < 0.05)). Findings summarized a significant decline in Krox-20 expression in degree of 
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 disability 1 compared to degree of disability 0 (T-test, F = 8.881, p = 0.000 (<0.005)). Sensitivity 
and specificity can be 100%. It means that if the Krox-20 expression is more than 8, the degree 
of disability will be 0 and vice versa. ROC curve showed that area under the curve is 1.0 
(100%) with p = 0.000. On the other hand, in patients with degree of disability 1, it can be seen 
that the expression of Krox-20 is minimal [16].
The function of Schwann cells is to synthesize the myelin sheath. When these cells are infected 
by M. leprae, the consequence is a demyelination resulting from neuritis. It is suspected that 
M. leprae infection in Schwann cells is a direct cause of Schwann cell dysfunction that can 
cause demyelination in leprosy patients [2].
Leprosy is one of the diseases that can cause nontraumatic nervous system disorder and is 
most commonly found in the world. Diagnosis of this disease can be established relatively 
easily because it does not require sophisticated equipment. The problem is the number of 
disabilities even though M. leprae has been eradicated in accordance with the applicable 
protocol. Early identification of the occurrence of disability is also the constraint in estab-
lishing diagnosis of disability as a sequel of leprosy. Nerve cell damage by leprosy is the 
result of the demyelination of peripheral nerve cells. Demyelination is caused by the entry 
of M. leprae into Schwann cells as the main target. The entry of these bacteria can cause 
the demyelination of Schwann cells suspected through the activation of the c-Jun pathway. 
When damage occurs in Schwann cells, automatically as a form of defense, Schwann cells 
will repair the damage that occurs, namely, by remyelination. The process of remyelination 
is influenced by NRG1 and NGF as a neurotrophic factor, as well as the availability of 
PMP22 and P0 as specific basic materials of myelin in peripheral nerves. Until now, based 
on the literature review we have read, the factors used to determine early disability in lep-
rosy patients are unknown. Meanwhile, the use of WHO criteria to determine the degree 
of disability is still rough because it involves only three sensory organs: feet, hands, and 
eyes. This study is aimed to determine the early markers of nerve damage, namely, demy-
elination and remyelination in leprosy patients with degrees of damage 0 and 1 based on 
WHO criteria.
2. Literature review
2.1. Leprosy in general
2.1.1. Definitions
Leprosy is a chronic granulomatic infection caused by M. leprae. This disease attacks the skin, 
nasal mucous membranes, and peripheral nerves [17].
2.1.2. Etiology
The cause of leprosy is M. leprae which is transmitted by droplet from nasal secretions and 
received by the nasal mucosa and other respiratory tracts. This bacterium mainly attacks 
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Schwann cells in the peripheral nervous system and can cause peripheral nerve functional 
disabilities as well as disability [18].
2.1.3. Epidemiology
Multidrug therapy (MDT) program has greatly reduced the prevalence of leprosy to less than 
1 case per 10,000 people in 90% of endemic countries where leprosy is considered as a public 
health problem. However, the leprosy case detection rate is still high [19].
2.1.4. Diagnosis
Based on physical examination, according to the WHO, there are three special physical signs 
for leprosy which can already be used to make the diagnosis. The three special signs are:
1. Redness or hypopigmented skin lesions with loss of sensation (especially sensation of 
touch and temperature)
2. Peripheral nerve involvement, such as peripheral nerve thickening with loss of sensation 
(especially touch and temperature)
3. Acid-resistant bacteria in the skin smear of the patient in a certain place
The diagnosis of the degree of disability in leprosy patients is based on the criteria published 
by the WHO as shown in Table 1.
The main classification according to WHO leprosy disease consists of paucibacillary (PB) and 
multibacillary (MB). If five hypopigmented patches can be found in the patient’s skin and 
there is no BTA in the skin smear, it can be classified as PB type. However, if more than five 
leprosy hypopigmentations are spotted, and/or BTA are found in skin smear, it may be con-
sidered as MB leprosy patients [19].
Symptoms
Hands and feet
Grade 0 No anesthesia, deformity, or structure damage
Grade 1 There is anesthesia, no deformity
Grade 2 There is anesthesia and deformity
Eyes
Grade 0 No problems with the eyes
Grade 1 Eye problems due to leprosy, visus is not worse than 6/60 or finger count on 6 m
Grade 2 Some severe disorders (visus < 6/60, unable to count fingers, and lagophthalmos, iridocyclitis, and 
opacity of the cornea)
Table 1. Assessment of the degree of disability and deformity index (hands, feet, and eyes) according to the WHO [20].
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2.1.4.1. Monofilament test
One of the techniques which is used to assess neuronal function in leprosy patients is monofila-
ment test (MFT). The test is performed using five different single filaments, i.e., 200 mg, 2 g, 
4 g, 10 g, and 300 g. Each site is then assessed by the perceived filament, which is the heaviest 
monofilament obtained and the highest value with a total value of 15 for the ulnar, median, and 
radial (four filaments) nerves and a total value of 12 for the foot (three filaments). The normal 
threshold value  is 200 mg for the hand and 2 g for the foot (other than the heel) [10, 11]. This test 
is considered positive if the MFT value is 3 for each nerve. “Fixed” or “unchanged” test result is 
when the test score has one- or two-point difference from the previous test score (basal value). If 
the value increases by three points or more, it is said to be “damaged” or “broken.” If the value 
decreases three points or more, it is said to be “improved.” If the patient’s examination value 
improves by three points or more, and the total value of the neural examination is reduced by 
two points or less when compared to the current patient condition, it is said to be “cured.”
For the ulnar, median, and posterior tibial nerves, the same examination as the INFIR study is 
performed, except for the median nerve on the tip of middle finger rather than the little finger 
(Figure 1).
2.1.5. Therapy
Patients with PB type can be given two types of drugs which are already available in the pack-
age. The first is for 6 months, i.e. In PB case, in patients over 15 years old, the drug is given 
in multidrug treatment (MDT) form with rifampicin 600 mg and dapsone 100 mg on the first 
day, the second day, and until the 28th day and so on for up to 6 months. The second is for 
1 year, i.e., MB case. In patients over 15 years, rifampicin 600 mg, clofazimine 300 mg, and 
dapsone 100 mg on the first day of the first month can be given. In the second and subsequent 
days, they are given dapsone 100 mg and clofazimine 50 mg [19].
2.1.6. Prognosis
In general, the prognosis of leprosy after getting the correct treatment is good. Healing in complica-
tions of neurological disorders is very limited, which means they are difficult to heal. Lesions on 
the skin can usually be healed in the first year of treatment, while color disorder of the skin and skin 
damage usually persist. Physical therapy, reconstructive surgery, nerve and tendon transplanta-
tion, and surgical operations to correct contractures can improve the patient’s quality of life [20].
2.1.7. Complications
Good care and attention to the possibility of reversal reactions due to leprosy treatment will 
minimize long-term neurological sequelae. Here are some possible leprosy complications:
2.1.7.1. Reaction type 1:
Slow hypersensitivity reaction occurs when BL leprosy shifts into LL leprosy during treat-
ment. This reaction is a description of good immune response and formation of IFN-γ and 
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Figure 1. Semmes-Weinstein monofilament testing points [21].
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TNF-α locally. This reaction is characterized by edema and erythema in skin lesions, the for-
mation of skin lesions, neuritis, and loss of sensation and motor. The incidence of type 1 
reactions in leprosy patients with BL is about 30%. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) and high-dose steroids can be given in the treatment of type 1 reactions.
2.1.7.2. Reaction type 2:
It is often referred to as erythema nodosum leprosum (ENL), which is the complication of LL 
type. This reaction is characterized by the formation of subcutaneous inflammatory nodules 
with fever, lymphadenopathy, and arthralgia. High levels of TNF-α and deposition of the 
immune complex are suspected to be closely related to ENL.
In addition, a complication that may also occur is Lucio phenomenon, which is a severe com-
plication in MB-type leprosy characterized by bluish bleeding plaque and necrotic ulceration. 
In this phenomenon, leprosy bacteria may have spread to endothelial cells along with the 
appearance of necrotic and vasculitic epidermis with thrombus formation and endothelial 
proliferation [6, 20].
2.1.8. Immunoprophylaxis and chemoprophylaxis
Bacille Calmette-Guerin (BCG) vaccine has been widely used in leprosy endemic countries to 
provide protection against leprosy. The first dose of BCG provides protection between 14 and 
80% against leprosy, while the second dose provides protection between 0 and 50%. Single dose 
of rifampicin administered to close contacts from newly diagnosed leprosy patients shows an 
efficacy of 57% in reducing new cases of leprosy [22]. Other studies show the protective effect 
of immunoprophylaxis and chemoprophylaxis in controlling leprosy. This is done by giving 
BCG vaccine at infancy in combination with rifampicin given to leprosy contacts. However, 
the effect of this combination is more useful for PB form contacts rather than MB form [23].
2.2. The peripheral nerve as a target of M. leprae
The Schwann cell (SC) of the peripheral nervous system (PNS) is essential for the survival and 
function of neurons, that is, to enclose axons. SCs were discovered by Theodore Schwann who 
investigated peripheral nerves. The function of this SC is to assist the myelination of axons 
and to direct the neurons. SC develops after birth from immature cells to become myelin or 
without myelin. The first immature cells go through the myelination path at birth and then go 
through the non-myelin path later in its development [24].
Both SCs which are myelin and without myelin produce an extracellular matrix that forms 
basal lamina containing collagen around axons. These neurons consist of units of axon cells—
Schwann and some neurons (fascicles) surrounded by solid fibrous tissues enveloping the 
perineurium. Furthermore, these fascicles are also grouped and create neural stems sur-
rounded by other tissues called the epineurium.
Myelinated SCs form myelin that surrounds large axons to increase the conductivity of neu-
rons. The unmyelinated SC surrounds several small axons separated by the cytoplasm. Myelin 
is formed by the differentiation of the plasma membrane of SC. Myelin consists of multilay-
ered membrane that encloses the axon in both the CNS and PNS. This helps in increasing the 
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speed of nerve impulses along the axon. Myelin contains 80% fat and 20% different proteins 
between the PNS and CNS [25, 26]. The major lipid classes found in other membranes are 
also found in myelin such as neutral lipids, phosphoglycerides, and sphingolipids. However, 
myelinated PNS has more sphingomyelin (10–35%); higher content of monogalactosylsphin-
golipid, cerebroside [Gal-C] (14–26%), and sulfatide [SGal-C] (2–7%); and less galactolipid 
and cholesterol than CNS myelin. The main fatty acid in myelinated PNS is oleic acid [C18: 1 
(n − 9)] (30–40% of total fatty acids). Myelin is also characterized by a very high long-chain fatty 
acid (>18 carbon). The long-chain fatty acids contained in sphingolipids are mostly saturated 
fatty acids. Myelinated PNS proteins are enriched in glycoproteins and basic proteins [25, 27].
The main proteins of the PNS are 28 kD myelin Protein-0 (P0) 50–60% and 100 kD myelin 
associated glycoprotein (MAG); both proteins presented only with myelinated SC to maintain 
the myelin solid structure and the integrity of the axons-myelin. Peripheral myelin protein-22 
(PMP-22 kD), myelin basic protein (MBP, 15%), and myelin P2 (10%). Both MBP and P2 myelin 
are located in the cytoplasm. Other heavy molecular mass of glycoproteins such as 170 kD peri-
axin are present in small amounts. Myelin P0, an immunoglobulin-like immune cell protein, is 
immutable among species, with various posttranslational modifications such as phosphoryla-
tion, acylation in amino acid regions 110–119, and glycosylation with single, N-linked nine 
asparagine sugar chains 93 [25]. MBP in the PNS has four polypeptide bands ranging from 14 
to 21 kD. This structure has various posttranslational modifications such as phosphorylation 
and methylation, and this is one of the major autoantigens in multiple sclerosis disease. Myelin 
P2 or fatty acid-binding protein 8 is a small protein (14 kD) with a high positive charge and is 
concentrated mainly in thick myelin sheaths. This structure is a member of the family of fatty 
acid-binding proteins with a high affinity for oleic acid, retinoic acid, and retinol. This structure 
function is to assemble and maintain myelin lipids. P2 is also an autoantigen in autoimmune 
peripheral neuropathy, Guillain-Barre syndrome (GBS). Its function is related to stabilizing the 
dynamics of myelin membranes and transport to and from lipid membranes [26, 27].
Myelin is only produced if the cell is in contact with several types of axons. Axons send signals 
that are important to identify the SC. Examples of axon signals are beta-neuregulin-1 (NRG1) 
and glial growth factor (GGF). SC can be activated to enter proliferation via axonal signaling 
NRG1 to bind and activate the ErbB2/ErbB3 receptor complex on SC to activate MAPK for cell 
proliferation. The factors governing myelination of SC include transcriptional factors Krox-
20, Oct-6, and Sox-10; they also inhibit cell death and proliferation. Special myelin protein, 
P0 for diminished myelinated SC if immature cells are not associated with axons. If SC loses 
interaction with an axon, there can be dedifferentiation into an immature SC. If the cells asso-
ciate with their axon again, they will become myelinated or nonmyelinated depending on the 
stimulating signal. SC has the ability to block apoptosis through the effects of growth factors 
such as insulin-like growth factors (IGFs), platelet-derived growth factor-BB (PDGF-BB), and 
neurotrophin-3 (NT-3) on autocrine circuit [24].
One of the events associated with SC pathogenesis is nerve injury and demyelination. This 
can be due to axonal damage and axon-SC signal interference. Another cause is the immune 
stimulation (autoimmunity) that targets myelin as in multiple sclerosis and Guillain-Barre 
syndrome (GBS). As with autoimmune disorders, M. leprae causes peripheral nerve demy-
elination that begins with damage to the myelin sheath and decreases the speed of the action-
potential conduction [28].
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2.3. Nerve damage in leprosy
Nerve damage is a major characteristic of leprosy pathogenesis. The first stage of nerve dam-
age in leprosy is the localization of M. leprae in peripheral nerves. A recent research about 
leprosy in experimental animal armadillos successfully revealed that after M. leprae success-
fully penetrate the skin barrier, these bacteria gather in epineurial lymph and blood vessels 
around the nerve and then go into the endoneurium compartment through the blood supply. 
However, if M. leprae can enter SC freely through the only way through the Schwann cells 
exposed to the dermis; the only way to prevent transmission of leprosy is to prevent the 
attachment of leprosy to Schwann cells [2].
In a study by Harboe et al., it is declared that M. leprae binds to the G domain of the α2-laminin 
chain (LN-α2) expressed by the Schwann cell axons. In addition, it is shown that αβ-dystroglycan 
(DG) in the basal lamina acts as complex receptor of LN-α2/M. leprae bonds. Presumably, there 
are other receptors that play a role in Schwann-M. leprae cell interactions because blocking of 
these receptors has not been successful in completely preventing the attachment of M. leprae. 
The third stage is the role of LBP-21 protein (LPS-binding protein, 21 kDa) which is surface 
antigen of M. leprae which acts as adhesin molecules to interact with Schwann cells. In addi-
tion, other M. leprae surface antigens sphingoglycolipid-1 (PGL-1) are also shown to bind to 
laminin-2. Therefore, PGL-1 is also involved in the Schwann cell invasion via the basal lamina 
via laminin-2-dependent pathway. It is suspected that PGL-1 serves as a second receptor to M. 
leprae where the combination of PGL-1 and LBP-21 provides sufficient energy in binding to 
Schwann cells so that M. leprae can enter Schwann cells safely [6].
The reversal reaction in leprosy is closely related to the increase of immense cellular immune 
reactions against mycobacterial antigens. Histologically, the lesions are invaded by mononu-
clear cells and result in edema and hyperemia. These events are the basis of immunosuppres-
sant administration in leprosy reactions, while antimycobacterial drugs should be continued 
as well. In the study, TNF-α and TNF-α mRNA levels were very high. This suggests a strong 
immunological reaction to M. leprae antigens.
Contact-dependent demyelination induced by M. leprae in nerve culture in the absence of 
immune cells also shows the role of nonimmune mechanisms during early infection and 
nerve involvement in leprosy infection. During the development of acute ENL with type 2 
cytokine pattern in leprosy patients, there is an increase in IL-6, IL-, and IL-10 as well as the 
persistent expression of IL-4 and IL-5 mRNAs in the lesions. Chronic ENL often leads to nerve 
damage, which is possible due to induction of local immune complex deposition with granu-
locytes that cause tissue damage and complement activation.
The c-Jun molecule is a major component of complex transcription of transcription factors and 
forms JunB and JunD in the Jun mammalian protein family. The c-Jun molecule is involved 
in cellular functioning and dependent on N-terminal phosphorylation performed by the Jun 
N-terminal kinase (JNK) enzyme. Thus, JNK can affect protein content of c-Jun. The levels 
of c-Jun in Schwann cell culture are high despite the simple culture medium. The c-Jun pro-
teins are present in immature Schwann cells on embryonic and neonate nerves, but their 
presence is suppressed in individual cells as transcription factors of Krox-20 premyelination 
are activated and the myelinating begins. In Schwann cell culture, the addition of Krox-20 
expression is sufficient to suppress the expression of c-Jun protein. Krox-20 is also involved 
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in c-Jun  suppression in vivo, as c-Jun levels remained high in the Krox-20 null nerve where 
myelination is discontinued. In vitro experiments indicate that c-Jun suppression is abso-
lutely necessary for myelination processes since Schwann cells with high c-Jun expression 
will be inhibited in the myelination process of the axon in which the induction of Krox-20 
or cAMP myelin genes is inhibited. In contrast, in Schwann c-Jun null cells, it has increased 
myelinated gene expression [29].
c-Jun will be upregulated rapidly after nerve injury. This is a procedure that triggers the 
dedifferentiation of Schwann cells. To determine the function of c-Jun under these conditions, 
Arthur-Farraj et al. made the Schwann cell without c-Jun. The process of myelination at the 
stage of development is not so affected on the specimen. However, it turns out that c-Jun is 
normally suppressed as the myelination process begins. However, after the process of injury 
passed, there is a delayed degradation of the myelin sheath. This presumably occurs because 
of decreased ability of c-Jun null cells in digesting myelin. In addition, there is a delay in the 
inactivation of myelin genes and the failure to activate the necessary molecules of demarcated 
cells including L1, p75NTR, and N-cadherin. All of these molecules are important because 
after the injury, c-Jun protein required Schwann cells to differentiate and adjust the molecular 
phenotype as it is immature. One of the properties that can be known when the cell is defi-
cient or when there is disruption of c-Jun in Schwann cells is the loss of regeneration ability 
dramatically and the loss of recovery ability after injury [30].
The key role of axon integrity in controlling switches from c-Jun negative, positive Krox-20 
which functions in maintaining myelin differentiation, to positive c-Jun; negative Krox-20 in 
dedifferentiated cells can be clearly observed in experiments using Wild mice. In these mice, 
axonal degeneration and myelin degradation that occur after neural cuts are delayed for up to 
2–3 weeks. It is presumed that during the period of maintenance of myelin after an axotomy, 
the expression of Krox-20 is maintained and c-Jun is inhibited. At the time when axons degen-
erate and the myelin sheath begins to break down, c-Jun is expressed, while Krox-20 is no 
longer expressed [31].
2.4. Immunopathogenesis nerve damage in leprosy
2.4.1. Immune-mediated damage
2.4.1.1. The role of cellular immunity
SC can take, process, and present the specific antigen of M. leprae to T cells resulting in the pro-
duction of Th1 modulatory immune cytokines such as TNF-α and INF-γ [32]. SC can present 
mycobacterial antigen to MHC class I, CD8+ cytotoxic T cell, and also can present mycobacte-
rial antigen to class II MHC, CD4+ CTLs. SC was found to express co-stimulatory molecules 
and adhesions to T cells. As a result of this stimulation, SC will be killed by cytotoxic granules 
(granulysin, granzyme, and perforins) produced by CTLs [33]. SC can express TLRs (TLR1 and 
TLR2) which are activated by LAM M. leprae, a lipoprotein such as 19 and 33 kD. SC activation 
will lead to cytokine production (TNF-α, IL-12) and apoptosis [34]. TLR expression was found 
to be greater in TT patients than LL patients [35]. The large amount of cytokines released by 
Th1 cells, especially IL-12, IL-2, and TNF-α, will cause apoptosis of infected cells and decrease 
in bacterial load and increase granuloma formation such as lesions in TT type [36].
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Macrophages also play role in the stimulation of immunity in leprosy. Infected macrophages 
by M. leprae can present its antigens to T and B cells and release cytokines including TNF-α 
[1]. Both of these cells can produce reactive oxygen intermediate (ROI) which results in fur-
ther nerve damage at the site of granuloma [26]. M. leprae stimulates macrophages to produce 
TGF-β which is responsible for decreased nerve regeneration [26]. Other cells may also pres-
ent antigens which are dendritic cells, also found to effectively present the M. leprae antigen 
and stimulate CD4+ and CD8+ cytotoxic T cells. Th1 cells are thought to be involved in CMI-
DTH reactions (cell-mediated immunity-delayed-type hypersensitivity) and are important in 
response to intracellular pathogens. In contrast, Th2 cytokines stimulate the production of 
antibodies. C-type lectin DC-SIGN shows binding to LAM and triggers the production of 
IL-10 and TGF-β and inhibits the production of IL-12 and TNF-α [37].
Scollard proposes that M. leprae interacts with the vascular endothelial cells and perineurium 
before successfully infecting the SC. This leads to the possibility that M. leprae infects the 
peripheral nerve tissue through the bloodstream [2]. This mechanism is thought to play an 
important role in SC immunopathogenesis and peripheral nerve damage to leprosy.
2.4.1.2. The role of humoral immunity
High levels of antibodies (IgM and IgG) are usually found in LL-type leprosy patients. Th2 
(IL-4, IL-5, and IL-10) cytokines found in LL patients decrease TLR2 expression and stimulate 
activation of B cells. Activated B cells can make IgM, IgA, and IgG antibodies ineffective in 
killing intracellular bacteria. Therefore, M. leprae is able to survive and spread, causing vari-
ous nerve damages [38]. After chemotherapy, there is usually a decrease in antibody levels. 
There is a strong correlation between bacterial load and humoral immune response. Analysis 
of antibody response has also been proposed as a tool for leprosy classification [39].
The antibodies produced against M. leprae play a role in the uptake of M. leprae by phagocyte cells 
and initiate the pathogenesis of the disease. For example, the discovered antibodies are binding 
to complement, which then binds PGL-I and binds C3 complement to M. leprae. The binding of 
this complement will mediate the uptake of bacilli through complement receptors in phagocytes 
[40]. In addition, secreted antibodies can form immune complexes with M. leprae antigen or with 
cross-reactive host molecules. This complex can then be recognized by antigen-presenting cells 
through specific receptors and delivered to T cells. In LL patients an excess of immune complex 
antibodies is found. However, if the antibodies are taken by APC cells (macrophages), they fail 
to activate T cells. Specific mature B-cell markers (CD20, CD79, CD138) that produce antibodies 
are found to be higher in skin lesions of BL/LL patients than BT patients [41]. In addition, when 
compared to gene expression of leprosy skin lesions of LL and TT types, it showed upregulation 
of B-cell-specific gene. Immunohistology of LL and TT skin lesions showed that IgM and IgA 
are more common in LL-type leprosy lesions, correlated with Th2 immunity and increased IL-5. 
LL is associated with an increase in systemic humoral response [42].
Another proposed mechanism which can cause neuropathy in leprosy and is also associated 
with stimulation of the immune response during infection is autoimmunity. The concept and 
general criteria of autoimmunity in leprosy have been established since 1969. It was found 
that in leprosy, an increase in immune complex (1gG-IgM, IgG-IgA, and complement compo-
nents) is similar to other autoimmune diseases such as systemic lupus erythematosus (SLE), 
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Guillain-Barre syndrome (GBS), and rheumatoid arthritis. The formation of antigen-antibody 
complexes and complement stimulation as well as the recruitment of PMN cells can cause 
tissue damage and injury to the vessel wall as seen in autoimmune and leprosy diseases [42].
T cells in leprosy lesions may be produced either against specific antigens of M. leprae or 
autoantigens such as HSP-66. This may cause other mechanisms of nerve damage caused by 
autoimmune damage such as from tissue (neuropathy). In LL-type leprosy patients, there was 
a decrease in the specific antigen level of T cells against M. leprae antigen 65 kD, but at the 
same time, there was an increase in anti-antibody levels of 65 kD IgG. The similarity between 
bacterial proteins and host components or the presence of molecular mimicry is an important 
aspect for host-pathogen interactions. By using this mechanism, pathogen can avoid detection 
by the immune system or may cause autoimmunity. The monoclonal antibodies that arise 
against M. leprae antigens such as 65 kD antigen react with host antigens such as peripheral 
axons found in the skin.
In addition, the protein sequence of myelin PNS P0 is compared to the M. leprae protein 
sequence (leproma) and also other genomic databases for protein sequences and structural 
equations in other pathogens involved in neurodegeneration. This resulted in 11 hits with the 
right pair ranging from six to seven P0 myelin residues in the M. leprae genome, but not in other 
genomes of mycobacteria. Among these, two suitable on M. leprae are special proteins including 
ferredoxin NADP reductase (62%) and conserved membrane protein (36%) (ML2453, ML1504). 
Comparisons to other pathogen databases show that P0 has similar sequences with polio virus 
receptors (23.4%) and herpes virus (4%). In addition, searching for the myelin P0 sequence 
on the whole genomic database revealed that it has similar sequence to the immunoglobulin 
superfamily. This family plays an important role in the interactions of proteins-proteins and 
protein-ligands. The similarity between bacteria and host is that they can cause autoimmunity 
and neurodegeneration (demyelination) as can be seen in leprosy transmission. For example, 
anti-neural antibodies from serum of leprosy patients were found to bind the myelin protein P0.
Some autoantibodies found to be important in leprosy patients from western India with 50% 
detected in LL, 44.4% in BL, and 54.8% in BT. These autoantibodies are antinuclear antibodies 
(ANA), anti-double-stranded DNA (dsDNA) and anti-single-stranded anti-DNA (ssDNA), and 
antinuclear antigens (anti-ribonucleoprotein (nRNP), anti-Smith and anti-histone antigen (AHA)).
Since leprosy is one of the differential diagnoses of rheumatic diseases, some autoantibodies 
can be examined in leprosy serum using ELISA techniques and correlated with joint involve-
ment. For example, in Brazil, most leprosy patients have no active reaction. Therefore, the fre-
quency of IgM-rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody, 
antinuclear antibody (ANA), and antineutrophil cytoplasmic antibody (ANCA) is low in lep-
rosy patients. However, the prevalence of anticardiolipin (aCL) antibodies and anti-β2 glyco-
protein I (β2GPI) antibodies is significantly higher in leprosy patients than in the control group.
Glycolipids and glycosphingolipids expressed as determinants of myelin surfaces in SST are 
important for the function and stability of myelin itself. The resistance to these molecules 
(glycolipids) by autoantibodies can cause demyelination and nerve damage as found in lep-
rosy patients. Therefore, many scientists study the autoantibody and its relationship to nerve 
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damage found in leprosy. Glycolipid or glycosphingolipid neural antibodies such as ceramide 
have been studied in leprosy patients in India. The anti-ceramide antibody IgM titers were 
found to be significantly higher in MB-type leprosy patients than both control and PB leprosy 
patients (96% of MB-type and 60% of PB-type patients). Groups in Brazil found elevated levels 
of anticardiolipin (aCL) and anti-β2-glycoprotein I (anti-β2-GPI) in leprosy patients, especially 
in LL-type patients with IgM-isotype dominant. The percentage of antiphospholipids in lep-
rosy can be due to exposure to phospholipid antigen by tissue damage during the infection 
process. Another explanation is that the homology between PL bacteria and host results in the 
production of antibodies against cross-reactive heterological sequences.
Other anti-glycolipid antibodies are anti-sulfatide (cerebroside) which has also been reported 
in various cases of demyelinated peripheral polyneuropathy. Sulfatide, a glycolipid with 
single sulfate saccharide, is associated with the myelin membrane of nerve cells. Antibodies 
inhibit sulfatide synthesis expressed on myelin as a surface determinant, resulting in demy-
elination. IgM-subtype antibodies against sulfatide were increase in MB- or LL-type leprosy 
compared to PB and control. IgM anti-sulfatide is positively correlated with the patient’s bac-
terial index. The similarity between mycobacterial sulfolipid with trehalose sulfate and host 
tissue (sulfatide) can stimulate autoantibodies against host sulfatide with galactose sulfate.
Variations in the number of autoantibodies found in leprosy patients can be attributed to 
the genetic background of the study population, the presence of infectious diseases, and the 
techniques used to detect autoantibodies. The hypothesis proposed for the development of 
such antibodies during infection is due to adaptive immune responses and activation of poly-
clonal B cells. Bacterial or viral antigens, with homologous sequences to tissue hosts, will 
be presented to T lymphocytes that stimulate B lymphocytes to produce antibodies against 
heterologous sequences.
In addition, autoantibodies to the antigenic epitope of myelin protein are reported in various 
chronic demyelinating diseases. For example, in chronic inflammatory polyradiculoneuropa-
thy (CIPD), in which both humoral and cellular immunities are involved, there are antibodies 
to the myelin protein. The major antigenic components of myelin are myelin P0, P2 myelin, 
and peripheral myelin protein 22 (PMP22). These proteins are also associated with induced 
experimental autoimmune neuritis (EAN). Such autoantibodies may be produced during tis-
sue damage and then continue to exacerbate further tissue damage during the disease process.
2.4.2. Demyelination without immunological process
Beside inflammatory process, axon demyelination can be caused by the presence of M. leprae. 
Rambukkana et al. have proved this both in vitro (in schwannn cell coculture) and in vivo (in 
Rag1−/− mice) had low levels of T cells and B lymphocytes. In this model M. leprae is able to 
induce demyelination within 24 hours postinfection without apoptosis or toxic effects on cells. 
The M. leprae component such as PGL-1 cell wall is also associated with the demyelination of 
SC in the model. Therefore, Rambukkana concluded that the survival of M. leprae was unnec-
essary in nerve demyelination induction in vitro and in vivo [5]. In addition, in his study M. 
leprae was found to be capable of inducing extracellular signals regulated by the Erk1/Erk2 
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kinase signal via the MAPK-MEK-dependent pathway. This activation caused by contact 
dependent between M. leprae and primary SC without apoptosis or cell death in SC. In this 
scenario, M. leprae is found to bind and induce the phosphorylation of ErbB2 receptors in SC 
other than laminin receptors located closely to ErbB2. As a result of this signal activation, M. 
leprae succeeds in inducing SC proliferation and demyelination [5]. Rambukkana stated that 
the mechanism of nerve damage in the absence of an immunological process played a role 
in the early stages of the disease. However, it is an immune system-mediated element that 
eventually causes nerve damage. When the M. leprae antigen is presented by myelinated and 
unmyelinated SC, both types of cells are subjected to attack by macrophages, T cells, and 
cytokines that are released as a result of the cell’s inflammatory response. This inflammatory 
process will produce two SC phenotypes and sensoric-motoric damage subsequently [5].
Another mechanism that is suspected to cause nerve damage can be grouped in the form of 
nonimmune mediated, and it is the biochemical and metabolic changes in the nerve compart-
ment. The examples of these mechanisms are axonal atrophy due to hypophosphorylation of 
myelin proteins and axonal neurofilament. Many proteins in PNS are phosphorylated such as 
myelin P0, MAP, and neurofilament proteins. An experiment which studied the phosphoryla-
tion of PNS proteins in leprosy nerves compared to normal nerves found that decrease in pro-
tein phosphorylation protein levels of 25 kD in leprosy patients’ nerves. The phosphorylated 
(25 kD) protein is thought to be the myelin glycoprotein P0 [43]. Later studies by the same 
group also found that M. leprae could bind these myelin P0 (25 kD) glycoproteins and inhibit 
phosphorylation in vitro. The outer binding of the myelin can help M. leprae to reach the SCs 
target for invasion [43].
The neurofilament protein belongs to the filament intermediate (IF) found together with the 
microtubules and microfilaments in the cytoskeleton structure. Other proteins that make up 
IF in vimentin, peripherin, internexin, and nestin neuron. The NFS protein (neurofilament) 
in the axon consists of triplet proteins, namely, the molecular weight of NF-H (high), NF-M 
(medium), and NF-L (low) neurofilament proteins. The neurofilament protein contains an 
amino-terminal head domain, which is central-helical domain, and terminal-carboxyl-tailed 
domain in various lengths. Increasing the total number of NF proteins in axon results in an 
increase of axonal diameter. In addition, the phosphorylation of NF proteins is important 
to determine the axonal caliber. NF-M and NF-H proteins are highly phosphorylated in the 
C-terminal tail domain on the replication of KSP (lysine-serine-proline) in myelinated axons 
(Chung-Ho Liang, 1996). Several studies have shown that NF-H migrates more rapidly in 
SDS-PAGE after extensive dephosphorylation by alkaline phosphatase. Several studies have 
demonstrated the important role of NFS in the growth of myelinated radial axon using NFS 
protein knockout gene.
In leprosy patients, a decrease in axonal diameter was found to be associated with the loss of 
sensoric and motoric function. Therefore, the relationship between neuropathy and phosphor-
ylation of NF protein was then investigated. The technique used was Western blot and immu-
nohistochemistry to examine the phosphorylated NF epitope (SMI 31) on leprosy patients’ 
nerves. In addition, Shetty et al. found the decrease or loss of SMI 31 in staining of infected 
nerve fibers. The NF protein band migrates faster (lower) than expected and decreases the 
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levels of NF protein content in the infected nerve. These results indicate the presence of hypo-
phosphorylated NF subunits during leprosy infection, which are thought to lead to increasing 
susceptibility to proteolytic degradation of NFS. This result is consistent with the previous 
research, where phosphorylation was found to protect NFS against nonspecific proteolysis by 
calpain. Several studies by Shetty et al. found that lipoarabinomannan (LAM) M. leprae could 
inhibit the protein kinase C (PKC) enzyme which is responsible for the phosphorylation of 
the neurofilament protein. Recently, Save et al. also found that hypophosphorylation of NFS 
proteins by measuring the activity of enzyme kinases is responsible for NFS phosphorylation 
in the nerves of infected mice. The authors point out that as long as NFS loses its reactivity to 
specific NF-phosphate (SMI 31) antibodies, there is a decrease in KSPXK kinase activity from 
cyclin-dependent kinase (CDK) and MAPK in M. leprae-infected nerves. Decreases in NFS 
phosphorylation and NFS degradation may subsequently result in decreasing in interfilamen-
tary distances that affect axonal growth and result in axonal atrophy.
In addition, M. leprae was found to induce upregulation of metalloproteinase matrix (MMP-2 
and MMP-9) in SC which causes demyelination and damage to the blood-nerve barrier (Teles, 
2010). The MMP protein family consists of proteolytic enzymes that participate in remodeling 
the extracellular matrix and the regulation of leucocyte migration. The function of MMP-2 is 
to degrade the type I collagen (gelatin), and the function of MMP-9 is to degrade the type IV 
collagen, which is a major component of the basal membrane. Increased MMP secretion is 
associated with tissue damage and can be used as a biomarker in many inflammatory disor-
ders. During mycobacterial infection there was an increase in MMP-9 secretion that correlated 
with TNF-α production. It was found that during tuberculoid leprosy and type I (RR) lesion 
reactions, MMPs increased in the central region of granuloma, where dominant macrophages 
and epithelioid cells were obtained.
Nerve damage in leprosy infection is divided into two stages: (1) early stage which has no 
inflammation cells. This phase is initiated by contact between M. leprae with SC in SST and 
causes nerve damage. This phase often occurs on the entire spectrum of leprosy. It is charac-
terized by sub-perineural edema, axonal atrophy, and demyelination with loss of myelinated 
nerve fibers. (2) The second phase is the phase which is mediated by inflammation with lym-
phatic cells in the form of tuberculoid and macrophage cells in lepromatous leprosy lesions. 
In this stage, the presence of autoantibodies against nerve components is reported in lep-
rosy as another mechanism of nerve damage. The presence of common antigenic determinant 
between M. leprae, the skin, and nerves such as heat-shock proteins leads to the production of 
autoantibodies [26].
The presence of M. leprae in the nerves can also cause leprosy neuritis which has no skin mani-
festation, but nerve damage can be detected. Nerve damage can be caused by a full inflamma-
tory inflammation of macrophages that produce foam cells in granulomas. This inflammatory 
process causes the stimulation of cytotoxic T-cell activity, axonal degeneration after SC death, 
and demyelination. Using different SC and axonal markers on the immunohistochemical 
slide of leprosy neuritic nerve, there was a decrease in immunoreactivity of NF200 as a result 
of the loss of myelinated fibers. In addition, the S-100 protein staining of the myelinated fibers 
was reduced due to loss fiber after the onset of demyelination. NGFr staining of the neuritic 
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nerve is also reduced in SC and/or small fiber axons. A decrease in myelinated fibers results 
in a decrease in MBP [44].
2.5. Schwann cells and their interactions with NGF, NRG, P0, and PMP22
2.5.1. Nerve growth factor (NGF)
Nerve growth factor (NGF) is firstly discovered in neurotrophin family. NGF is essential in 
the development and maintenance of phenotypic peripheral nerve cells and for the functional 
integrity of the cholinergic nerves in the central nervous system. The mature form of NGF 
(from ProNGF precursors) has an important role in development and in adult life and also has 
proapoptotic and neurotropic properties.
A study by Chan et al. about NGF in controlling axon receptivity on myelination by 
Schwann cells revealed that NGF is an axonal signal regulator that controls the myelina-
tion of nerve cells in the dorsal ganglia that expresses TrkA. NGF triggers the myelination 
by Schwann cells, but it inhibits myelination by oligodendrocyte cells. This reinforces that 
NGF plays a role in the Schwann cell myelination in the PNS.
2.5.2. Neuregulin 1 (NRG1)
In early life, Schwann cells are made of cells in neural plates and undergo massive migration, 
proliferation, and maturation before finally undergoing differentiation. During this period, 
Schwann cells are constantly in contact with axons and axonal signals, particularly neuregu-
lin-1 (NRG1). In fact, NRG is a signaling protein that mediates the interactions of cells in the 
nervous system, heart, breast, and other organ systems. Neuregulin is also ligand for the 
ErbB family of tyrosine kinase receptors. Neuregulin itself has four families, namely, NRG1, 
NRG2, NRG3, and NRG4. However, until now, the biological functions of NRG2, NRG3, and 
NRG4 are still not widely known [45]. NRG1 is a growth factor that is very influential on the 
development of cells in the neural plate during the early stages of embryonic development. 
NRG1 is also involved in migration, axon growth, and synapse formation [46, 47]. In addition, 
NRG1 is a strength for Schwann cells to differentiate. This is proven in cell cultures where 
many aspects of Schwann cells are administered by NRG1, which are:
1. NRG1 serves to suppress the neuronal differentiation of the neural stem cell plate but to 
stimulate the differentiation of glial cells.
2. NRG1 is required for Schwann cell progenitor survival.
3. NRG1 also serves to stimulate proliferation and migration of Schwann cell precursors.
4. NRG1 gives an important signal to myelinate.
In vivo, the early stages of Schwann cell development depend on NRG1/ErbB signaling, as 
in mouse-fed animals without Schwann cell progenitors in peripheral neuronal development 
such as ErbB2, ErbB3, or NRG1.
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2.5.3. Protein 0 (P0)
P0 or MPZ is one of the major protein components of myelin nervous system. P0 protein is 
transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is the largest 
part of protein in SST myelin and is thought to be responsible for the adhesion of the outer 
surface of the cell and the myelin plasma membrane [48].
2.5.4. Peripheral myelin protein 22 (PMP22)
Peripheral myelin protein 22 (PMP22) is a major component of myelin (Snipes et al., 1992). 
This is evidenced by the discovery of PMP22 mRNA in Schwann cells and the PMP22 protein 
in the solid part of the myelin sheath. Assessment of the presence of PMP22 as a peripheral 
nerve myelin protein is also supported by the finding that the regulation of PMP22 expression 
during neural development and after neuronal trauma is identical [16].
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